# Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

> **NCT03833154** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 724 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Durvalumab
- **OTHER:** Placebo
- **DRUG:** (Osimertinib cohort, single-arm, open-label separate cohort)

## Key facts

- **NCT ID:** NCT03833154
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-06
- **Primary completion:** 2028-10-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 724 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03833154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03833154, "Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03833154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*